Osteoporosis Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Products (Drugs (Antibodies, Bisphosphonates), Hormones (Parathyroid Hormone, Thyrocalcitonin, Selective Estrogen Receptor Modulators), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Region Forecast 2019-2030

Osteoporosis Treatment Market size was valued at US$ 14,103.8 million in 2023 and is anticipated to grow at a CAGR of 4.9% from 2024-2030. The market refers to the pharmacological and therapeutic interventions aiming for the management and treatment of osteoporosis. Osteoporosis is a medical disorder that develops when bone mineral density and bone mass decline, or when bone quality or structure changes, which can result in a loss in bone strength, increasing the risk of fractures. Osteoporosis treatment's primary purpose is to reduce bone loss, strengthen bones, and prevent fractures. Medication, lifestyle changes, and dietary supplements are among the therapeutic options available. Medications commonly prescribed for osteoporosis include bisphosphonates, selective estrogen receptor modulators (SERMs), hormone replacement therapy (HRT), and monoclonal antibodies which promise to improve overall bone health.  The market has witnessed significant growth due to the rising prevalence of osteoporosis worldwide, particularly among the aging population.

According to research study, more than 200 million people are estimated to have osteoporosis, and based on the latest data from the International Osteoporosis Foundation; one in every three women over the age of 50 and one in every five men will suffer from fractures associated with osteoporosis in their lifetime. As a result, there is a growing demand for effective osteoporosis treatments, which accelerates the growth of the market. The expanding geriatric population along with the advancements in novel treatment options presents a significant opportunity for the market. Apart from this, some of the recent trends such as rising adoption of biologic therapies and integration of digital health technologies are shaping the growth of the market. However, some osteoporosis treatments, such as bisphosphonates, may be associated with side effects, including nausea, abdominal pain, and heartburn-like symptoms which pose challenges for the growth of the market. Major pharmaceutical companies are continuously involved in research and development and launching new treatment options which further expands the market.

Key Developments

• In December 2022, Chugai Pharmaceutical Co., Ltd. and Towa Pharmaceutical Co., Ltd. launched Edirol Tablets 0.5 µg/0.75 µg (generic name: eldecalcitol, hereafter, Edirol Tablet) for osteoporosis treatment.
• In January 2023, Teijin Pharma Limited announced to launch Japan-market sales of abaloparatide acetate for osteoporosis under the tradename OSTABALO.